ГЕПАТОПРОТЕКТОРНЫЕ ЭФФЕКТЫ ПРЕПАРАТА МЕКСИКОР ® ПРИ ЛЕЧЕНИИ БОЛЬНЫХ ХРОНИЧЕСКОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ И САХАРНЫМ ДИАБЕТОМ 2 ТИПА

Abstract

The prospective, randomized, open-label 16-week trial studied Mexicor ® (part of complex treatment) effects in patients with chronic heart failure and type 2 diabetes mellitus, on structural and functional parameters of the liver. Hepatoprotecive facilities of Mexicor ® were demonstrated: a significant decrease in the severity of cytolysis, cholestasis, steatosis index, the ability to reduce severity of structural changes in the liver by ultrasound. These hepatoprotective effects are realized by Mexicor ® influencing on lipid peroxidation, activity of antioxidant enzymes, decreasing of chronic systemic inflammation expressions. The use of Mexicor ® promotes more evident associated hypoglycemic effect and reduces the severity of insulin resistance. Marked hepatoprotective effects of Mexicor ® improves not only metabolic processes in the liver, but also can significantly change the cardiovascular risk in these patients.

Keywords

• chronic heart failure
• type 2 diabetes mellitus
• nonalcoholic fatty liver disease
• mexicor®
• hepatoprotection